ArticleJournal of thoracic disease2025
Neoadjuvant arterial infusion chemotherapy combined with immunotherapy in treating locally advanced lower esophageal and esophagogastric junction cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment of locally advanced lower esophageal cancer/esophagogastric junction cancers still has certain limitations. This study shares a new therapeutic strategy, namely neoadjuvant arterial infusion chemotherapy combined with immunotherapy (neo-AICIT). Methods: The data of patients who received neoadjuvant arterial infusion chemotherapy (docetaxel + cisplatin) combined with immunotherapy (tislelizumab) for locally advanced lower esophageal cancer or esophagogastric junction cancers from October 2021 to May 2023 were collected. The indicators of these patients, such as the clinical staging of tumors, treatment-related adverse events (TRAEs), the effect of neoadjuvant therapy, operative complications, tumor regression grade (TRG), progression-free survival (PFS), and follow-up time, were recorded. Results: A total of 12 patients received a complete neoadjuvant regimen, sequential surgery, and postoperative maintenance immunotherapy. The median age was 61.5 years. All patients suffered from squamous cell carcinoma; eight of them had lower esophageal cancer and four had esophagogastric junction cancer. The clinical staging in all patients was cT3N0-2M0G1-3. The median tumor proportion score (TPS) was 32.5%. Only grade 1 TRAEs occurred during adjuvant therapy, and the incidence was 58.3% (7/12). Postoperative complications included pulmonary infection 16.7% (2/12) and recurrent laryngeal nerve injury 16.7% (2/12). The postoperative pathology showed that 11 (91.7%, 11/12) patients had major pathological remission (MPR) with a TRG of 1-2, while 7 (58.3%, 7/12) patients had pathological complete response (pCR) with a TRG of 1. The objective response rate (ORR) was 100%. The median follow-up time was 19.5 months. Two patients had mediastinal lymph node metastasis at 18 and 20 months after operation, respectively. Tumor recurrence or metastasis was not found in other patients. Conclusions: Observations of small case series suggest that neo-AICIT has good safety and efficacy in the treatment of locally advanced lower esophageal/esophagogastric cancer, and may be a promising neoadjuvant treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.